We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Axela Licenses Beckman's Universal Linker Capture Technology

By Labmedica staff writers
Posted on 20 Dec 2006
Axela Biosensors Inc. More...
(Toronto, Canada), and Beckman Coulter Inc. (Fullerton, CA, USA), have announced the signing of a nonexclusive licensing agreement that gives Axela rights to Beckman Coulter's patented A2 universal linker capture technology. The terms of the license were not disclosed. Axela will incorporate the technology into its dotLab Sensors, which will give scientists the unique ability to create user-defined multiplex biomarker panels.

Combining A2 universal linkers with the recently launched dotLab System allows scientists to create custom multiplex protein assays without the need for specialized pipetting or spotting techniques. Axela plans to use the technology in conjunction with its dotLab sensors to allow users to define their own biomarker panels and to use either the Axela library of pre-conjugated antibodies or their own reagents with universal linkers.

"The innovative Universal Linker approach will allow users to tag their own antibodies or draw from a library of existing markers to build combined assays with micromolar to picomolar sensitivity requirements,” explained Rocky Ganske, CEO of Axela Biosensors.

"Coupled with the dotLab System, this self-addressing DNA approach gives the translational scientist a simple and flexible method to perform multiplexed immunoassays, and has the potential to significantly transform the speed in which putative biomarkers can be validated.”

Axela Biosensors is commercializing products that accelerate the validation of protein biomarkers from discovery into routine clinical practice. The company has developed a proprietary breakthrough technology called diffractive optics technology (dot), which enables the real-time detection and quantitation of protein-binding events in complex media. Axela developed this technology into the dotLabSystem, a commercially available benchtop laboratory system that delivers simple, affordable, yet highly sensitive protein based assays. To leverage the opportunities that dot creates, Axela has assembled a management team with extensive experience in diagnostic and research product development and commercialization.

Beckman Coulter, Inc. manufactures biomedical testing instrument systems, tests, and supplies that simplify and automate laboratory processes.



Related Links:
Axela Biosensors
Beckman Coulter

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.